MarketPulse

patent cliffs

3 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Dividend Kings $JNJ and $ABBV Emerge as Forever Holdings for Patient Investors

Dividend Kings Johnson & Johnson and AbbVie offer 50+ years of consecutive dividend growth with resilient pipelines successfully offsetting patent expirations.
JNJABBVABTpharmaceuticalsdividend stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Pharma Dominance: Why $LLY Attracts Long-Term Wealth Builders

$LLY dominates diabetes and weight management markets while diversifying into oncology and AI, positioning itself as a compelling long-term wealth-building investment within diversified portfolios.
NVDALLYlong-term investingdividend reinvestment
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Pfizer's Boring Appeal: Why Blue-Chip Stability Beats Biotech Hype

Pfizer's reasonable valuation, robust pipeline, and 6.4% dividend yield offer disciplined returns versus speculative biotech like Regencell, whose 21,000% surge lacks fundamental justification.
PFERGCstock valuationclinical trials